MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
(2009) European Journal of Cancer — Vol. 45, n° 1, p. 146-153 (2009)
Files
SadonesJ-EurJCancer2009.pdf
Restricted Access - Adobe PDF
- 152.54 KB
Details
- Authors
- Abstract
- MGMT promoter methylation predicted a survival benefit in patients with 1p/19q intact AA/AOA treated with temozolomide at recurrence.
- Affiliations
Citations
Sadones, J., Michotte, A., Veld, P., Chaskis, C., Sciot, R., Menten, J., Joossens, E. J. R., Strauven, T., D’Hondt, L., Sartenaer, D., Califice, S. F. E. H., Bierau, K., Svensson, C., De Grève, J., & Neyns, B. (2009). MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. European Journal of Cancer, 45(1), 146-153. https://doi.org/10.1016/j.ejca.2008.09.002 (Original work published 2009)